1320 NEW ZEALAND GAZETTE, No. 52 17 MARCH 2005

Product:
Tritace
Active Ingredient:
Ramipril 5mg
Dosage Form:
Tablet
New Zealand Sponsor:
Aventis Pharma Limited
Manufacturers:
Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany
Aventis Pharma SpA, Scoppito, L’Aquila, Italy

Dated this 10th day of March 2005.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go1584

Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Product:
Stocrin
Active Ingredient:
Efavirenz 100mg
Dosage Form:
Capsule
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico
Note: This consent is valid for two years from 11 November 2005.

Product:
Stocrin
Active Ingredient:
Efavirenz 200mg
Dosage Form:
Capsule
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico
Note: This consent is valid for two years from 11 November 2005.\n
Product:
Stocrin
Active Ingredient:
Efavirenz 50mg
Dosage Form:
Capsule
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico
Note: This consent is valid for two years from 11 November 2005.

Product:
Stocrin
Active Ingredient:
Efavirenz 300mg
Dosage Form:
Film-coated tablet
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico
Note: This consent is valid for two years from 25 October 2005.

Product:
Stocrin
Active Ingredient:
Efavirenz 600mg
Dosage Form:
Film-coated tablet
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico
Note: This consent is valid for two years from 25 October 2005.

Dated this 10th day of March 2005.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go1583

Misuse of Drugs Act 1975

Medical Practitioners Who May Prescribe, Administer or Supply Controlled Drugs for the Purpose of Treating People With Drug Dependence

Pursuant to section 24 (7) (a) of the Misuse of Drugs Act 1975, I, David George Chaplow, acting under delegated authority from the Minister of Health, specify that

Dr Harsed Chima, Travis Medical Centre, 225 Travis Road, North Brighton, Christchurch; and

Dr Victoria Paula Flight, The Clinic, 192 Gloucester Street, Christchurch

are medical practitioners who may prescribe, administer or supply controlled drugs for the purposes of that section, with the following conditions:

(a) The prescription of controlled drugs for the treatment of dependence is limited to patients registered at the specified doctor’s practice who have been assessed as requiring substitution treatment for opioid dependence by a hospital or clinic specified under section 24 (7) of the Act; and

(b) authorisation of other medical practitioners to prescribe controlled drugs for the treatment of opioid dependence is limited to designated locums working in the authorising medical practitioner’s